Eriocalyxin B

Eriocalyxin B is a diterpenoid compound that can be isolated from Chinese herb Isodon eriocalyx. Eriocalyxin B exhibits multiple activities, such as anti-cancer, anti-inflammatory, and inhibition of adipogenesis. Eriocalyxin B is capable of inducing apoptosis and autophagy in tumor cells. Eriocalyxin B can be used in the research of cancers, autoimmune diseases, and other conditions^{[1][2][3][4][5]}. In Vitro:Eriocalyxin B (0-3.5 μM; 7 days) inhibits adipogenesis (IC₅₀: 2.745 μM) and suppresses the expression of key regulators of adipocyte differentiation, including C/EBPα, C/EBPβ, PPARγ, and FABP4 in 3T3-L1 preadipocytes^[1].
Eriocalyxin B (1.25-3.5 μM; 16-48 h) induces G2/M phase arrest and inhibits the expression levels of cell cycle regulators in differentiated 3T3-L1 cells^[1].
Eriocalyxin B (48 h) is cytotoxic to tumor cells such as A-549, MCF-7, SMMC-7721, SW-480, and HL-60, with IC₅₀ values ranging from 0.3-3.1 μM^[2].
Eriocalyxin B (0.35-2.25 μM; 24-72 h) inhibits cell viability, increases intracellular ROS production, and induces apoptosis and autophagy in MCF-7 and MDA-MB-231. The mechanism involves the inhibition of the Akt/mTOR/p70S6K signaling pathway^[3]. In Vivo:Eriocalyxin B (10 mg/kg; intraperitoneal injection; 27 days) exhibits anti-tumor activity in a mouse model of breast cancer^[3].
Eriocalyxin B (10 mg/kg; intraperitoneal injection; 18-28 days) has an ameliorating effect in a mouse model of experimental autoimmune encephalomyelitis (EAE)^[4].